MapLight Therapeutics, Inc. (MPLT) · Aug 13, 2026 · Other events

A clean schizophrenia win—and enough cash to reach the next big readouts

Above the bar — PANSS effect size 0.37, p=0.015; cognitive effect size 0.51, p=0.041

ZEPHYR hit its primary endpoint with a cognitive signal and manageable tolerability. The new financing funds Phase 3 and VISTA, but adds meaningful dilution.

The key catalyst was already telegraphed, but the result clears the trial’s success bar. Management had previously guided to a mid-August ZEPHYR readout, so timing was not a surprise. The new information is that the 210/3 mg twice-daily dose produced a statistically significant PANSS improvement, separated on multiple secondary measures, and showed a prespecified cognitive signal.

MeasureZEPHYR result

| PANSS total score, mITT effect size | 0.37; p=0.015 (ZEPHYR results)

| PANSS total score, completers | 0.50; p=0.002 (ZEPHYR results)

| Cognitive composite effect size | 0.51; p=0.041 (Prespecified cognitive endpoint)

| CGI-S effect size | 0.48; p=0.002 (Key secondary endpoint)

| Patients reaching target dose | 99% (Safety and tolerability)

| Serious or drug-related severe adverse events | None reported (Safety and tolerability)

The efficacy package is broader than a single positive headline. PANSS, global severity, positive symptoms, responder analysis and cognition all moved in the same direction. The cognitive result came from a prespecified impaired subgroup and was not significantly correlated with PANSS improvement, which gives the signal more weight than a purely exploratory claim. Still, this remains a Phase 2 result, and the registrational path depends on FDA feedback at the End-of-Phase 2 meeting (Business update; Corporate presentation).

The financing removes the near-term funding overhang, but it is not free. MapLight raised approximately $150 million at $11.38 per share through 9.20 million shares and warrants covering another 3.98 million shares (Item 1.01). Against 45.4 million weighted-average shares in the quarter, the transaction represents roughly 29% additional share-equivalent issuance before warrant exercise. Cash, cash equivalents and investments were $351.3 million at June 30, implying approximately $501 million of gross pro forma liquidity before fees and expenses (Cash position; Corporate presentation).

The underlying quarter shows an accelerating spend profile, while the pipeline is being narrowed. Net loss rose to $60.2 million from $29.8 million year over year, with R&D expense increasing to $53.4 million from $26.8 million and G&A to $10.1 million from $3.8 million (Condensed Consolidated Statements of Operations). Management is pausing further investment in discovery and preclinical programs to concentrate capital on ML-007C-MA. That makes the positive ZEPHYR result more important: the company is now placing substantially more of its value on one lead program, while ML-004 remains constrained by an IRIS primary-endpoint failure despite a promising adolescent irritability subgroup (Business update; IRIS results).

Net read: above the bar, with the financing making the clinical win more actionable. The filing is materially better than a routine quarterly update because ZEPHYR supports a Phase 3 advance, provides a potentially differentiating cognitive signal and extends funding through the planned VISTA and ZEPHYR-2 milestones. The main offsets are dilution, rising operating losses and a narrower pipeline—not enough to erase the central positive change in development risk.

What to watch next

VISTA topline results, second half of 2027

Original filing on SEC EDGAR

A clean schizophrenia win—and enough cash to reach the next big readouts | MPLT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.